Clinical Trials Arena August 8, 2024
Cost, efficiency, technology and new vectors are all likely advancements in the cell and gene therapy space over the next decade.
Easily one of the quickest developing spaces in the pharma space right now, cell and gene therapies are becoming increasingly investigated in a variety of indications.
The year 2024 started with a cell and gene bang, with the first CRISPR-based gene therapy Casgevy receiving the seal of approval from the US Food and Drug Administration (FDA). On August 8, the National Health Service in the UK announced it will be providing the therapy to sickle-cell patients.
Despite being some of the most advanced medicines on the planet, a great number of these medicines are developed and manufactured using pen...
Today's Sponsors
Today's Sponsor